Treg Destabilization and reprogramming

Implications for cancer immunotherapy

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

Regulatory T cells (Tregs) are an important contributor to the immunosuppressive tumor microenvironment. To date, however, they have been difficult to target for therapy. One emerging new aspect of Treg biology is their apparent functional instability in the face of certain acute proin-flammatory signals such as IL6 and IFNg. Under the right conditions, these signals can cause a rapid loss of suppressor activity and reprogramming of the Tregs into a proin-flammatory phenotype. In this review, we propose the hypothesis that this phenotypic modulation does not reflect infidelity to the Treg lineage, but rather represents a natural, physiologic response of Tregs during beneficial inflammation. In tumors, however, this inflammation-induced Treg destabilization is actively opposed by dominant stabilizing factors such as indoleamine 2,3-dioxygenase and the PTEN phosphatase pathway in Tregs. Under such conditions, tumor-associated Tregs remain highly suppressive and inhibit cross-presentation of tumor antigens released by dying tumor cells. Interrupting these Treg stabilizing pathways can render tumor-associated Tregs sensitive to rapid destabilization during immunotherapy, or during the wave of cell death following chemotherapy or radiation, thus enhancing antitumor immune responses. Understanding the emerging pathways of Treg stabilization and destabilization may reveal new molecular targets for therapy.

Original languageEnglish (US)
Pages (from-to)5191-5199
Number of pages9
JournalCancer Research
Volume78
Issue number18
DOIs
StatePublished - Sep 15 2018

Fingerprint

Immunotherapy
Neoplasms
PTEN Phosphohydrolase
Cross-Priming
Indoleamine-Pyrrole 2,3,-Dioxygenase
Inflammation
Tumor Microenvironment
Neoplasm Antigens
Regulatory T-Lymphocytes
Immunosuppressive Agents
Interleukin-6
Cell Death
Radiation
Phenotype
Drug Therapy
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Treg Destabilization and reprogramming : Implications for cancer immunotherapy. / Munn, David H; Sharma, Madhav D; Johnson, Theodore Samuel.

In: Cancer Research, Vol. 78, No. 18, 15.09.2018, p. 5191-5199.

Research output: Contribution to journalReview article

@article{903beef9ba3f49fc86beed727d9ea765,
title = "Treg Destabilization and reprogramming: Implications for cancer immunotherapy",
abstract = "Regulatory T cells (Tregs) are an important contributor to the immunosuppressive tumor microenvironment. To date, however, they have been difficult to target for therapy. One emerging new aspect of Treg biology is their apparent functional instability in the face of certain acute proin-flammatory signals such as IL6 and IFNg. Under the right conditions, these signals can cause a rapid loss of suppressor activity and reprogramming of the Tregs into a proin-flammatory phenotype. In this review, we propose the hypothesis that this phenotypic modulation does not reflect infidelity to the Treg lineage, but rather represents a natural, physiologic response of Tregs during beneficial inflammation. In tumors, however, this inflammation-induced Treg destabilization is actively opposed by dominant stabilizing factors such as indoleamine 2,3-dioxygenase and the PTEN phosphatase pathway in Tregs. Under such conditions, tumor-associated Tregs remain highly suppressive and inhibit cross-presentation of tumor antigens released by dying tumor cells. Interrupting these Treg stabilizing pathways can render tumor-associated Tregs sensitive to rapid destabilization during immunotherapy, or during the wave of cell death following chemotherapy or radiation, thus enhancing antitumor immune responses. Understanding the emerging pathways of Treg stabilization and destabilization may reveal new molecular targets for therapy.",
author = "Munn, {David H} and Sharma, {Madhav D} and Johnson, {Theodore Samuel}",
year = "2018",
month = "9",
day = "15",
doi = "10.1158/0008-5472.CAN-18-1351",
language = "English (US)",
volume = "78",
pages = "5191--5199",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "18",

}

TY - JOUR

T1 - Treg Destabilization and reprogramming

T2 - Implications for cancer immunotherapy

AU - Munn, David H

AU - Sharma, Madhav D

AU - Johnson, Theodore Samuel

PY - 2018/9/15

Y1 - 2018/9/15

N2 - Regulatory T cells (Tregs) are an important contributor to the immunosuppressive tumor microenvironment. To date, however, they have been difficult to target for therapy. One emerging new aspect of Treg biology is their apparent functional instability in the face of certain acute proin-flammatory signals such as IL6 and IFNg. Under the right conditions, these signals can cause a rapid loss of suppressor activity and reprogramming of the Tregs into a proin-flammatory phenotype. In this review, we propose the hypothesis that this phenotypic modulation does not reflect infidelity to the Treg lineage, but rather represents a natural, physiologic response of Tregs during beneficial inflammation. In tumors, however, this inflammation-induced Treg destabilization is actively opposed by dominant stabilizing factors such as indoleamine 2,3-dioxygenase and the PTEN phosphatase pathway in Tregs. Under such conditions, tumor-associated Tregs remain highly suppressive and inhibit cross-presentation of tumor antigens released by dying tumor cells. Interrupting these Treg stabilizing pathways can render tumor-associated Tregs sensitive to rapid destabilization during immunotherapy, or during the wave of cell death following chemotherapy or radiation, thus enhancing antitumor immune responses. Understanding the emerging pathways of Treg stabilization and destabilization may reveal new molecular targets for therapy.

AB - Regulatory T cells (Tregs) are an important contributor to the immunosuppressive tumor microenvironment. To date, however, they have been difficult to target for therapy. One emerging new aspect of Treg biology is their apparent functional instability in the face of certain acute proin-flammatory signals such as IL6 and IFNg. Under the right conditions, these signals can cause a rapid loss of suppressor activity and reprogramming of the Tregs into a proin-flammatory phenotype. In this review, we propose the hypothesis that this phenotypic modulation does not reflect infidelity to the Treg lineage, but rather represents a natural, physiologic response of Tregs during beneficial inflammation. In tumors, however, this inflammation-induced Treg destabilization is actively opposed by dominant stabilizing factors such as indoleamine 2,3-dioxygenase and the PTEN phosphatase pathway in Tregs. Under such conditions, tumor-associated Tregs remain highly suppressive and inhibit cross-presentation of tumor antigens released by dying tumor cells. Interrupting these Treg stabilizing pathways can render tumor-associated Tregs sensitive to rapid destabilization during immunotherapy, or during the wave of cell death following chemotherapy or radiation, thus enhancing antitumor immune responses. Understanding the emerging pathways of Treg stabilization and destabilization may reveal new molecular targets for therapy.

UR - http://www.scopus.com/inward/record.url?scp=85053189580&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053189580&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-18-1351

DO - 10.1158/0008-5472.CAN-18-1351

M3 - Review article

VL - 78

SP - 5191

EP - 5199

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 18

ER -